Infectious Diseases

Leading the Charge Against Infectious Diseases
Schedule a Call

Leading Infectious Disease Research

hVIVO provides unparalleled scientific capability in respiratory infectious disease research, underpinned by decades of virology expertise and a comprehensive suite of validated Human Challenge Models across influenza, RSV, hMPV, HRV, COVID19 and other priority pathogens. Supported by BSL2 and BSL3 facilities, inhouse model development, manufacturing and integrated early phase clinical and laboratory operations, our platform enables precise characterisation of host–pathogen dynamics and high resolution evaluation of novel vaccines and therapeutics.

Our Expertise

ICON_Human Challenge Trials

World leader in Human Challenge Trials

World leader in Human Challenge Trials with models for influenza, RSV, hMPV, HRV, COVID‑19, Influenza, and Malaria
ICON_Beds

State‑of‑the‑art Human Challenge Unit

State‑of‑the‑art Human Challenge Unit facility with Containment Level 3 (BSL‑3) and onsite BSL‑3 labs.  

ICON_Virology

Multiple Pathogen Capability

Expanded capabilities beyond respiratory diseases to pathogens including Dengue, Zika, Norovirus, and Bordetella pertussis
ICON_Participants

Over 80+ Human Challenge Studies delivered

Over 80+ Human Challenge Studies delivered, including the first SARS‑CoV‑2 challenge study, and the only commercially available fully characterised models for hMPV, RSV-B and Omicron

Infectious Disease Capabilities

Pathogen & Model Development

From validated off-the-shelf models to fully customised pathogen programmes, we build the scientific foundation your study needs. Explore our available models and how we develop new ones to your specification. 

virus-image (2)

 

Facilities & Infrastructure

 

Our state-of-the-art clinical and laboratory facilities - including Containment Level 2 and BSL-3 - are purpose-built for complex infectious disease research. Discover the infrastructure behind every study we run.

hVIVO_Vaccine_Research2

 

Infectious Disease Laboratory

Our integrated laboratory spans molecular, immunology, virology, and bacteriology platforms - all under one roof. See how our multifaceted capabilities generate the high-resolution data your programme demands.  

hVIVO_Lab_Services_ELISpot-1

 

Human Challenge Studies

 

With over 80 studies delivered and the world's only commercially available models for hMPV, RSV-B, and Omicron, we are the global leader in human challenge research. Find out how our models can accelerate your vaccine or therapeutic development. 

A Catchpole Presenting to Audience

 

Featured

EBOOK | Advancing Infectious Disease Therapy Development

Download hVIVO's guide to early-phase infectious disease development — human challenge models, modRNA vaccines, CMC strategy, and regulatory alignment.

1 min read
View

Related Resources

Explore the latest thinking from our infectious disease experts — from challenge model advances and regulatory strategy to laboratory innovation and early-phase development insights.
View all
Blog Article Laboratory

Automation Is Transforming Lab Productivity - and Unlocking New Scientific Possibilities

Leo Calvo-Bado
16 Jun 2026 6 min read
Blog Human challenge trials Trial design

The Early‑Phase Anchor: Why Medical Monitoring Matters Long Before the First Dose

Mariya Kalinova
Mariya Kalinova Medical Director London
23 Apr 2026 8 min read
Blog Human challenge trials Infectious diseases

From RSV to hMPV: Building the Next Generation of Respiratory Challenge Models

Andrew Catchpole
Andrew Catchpole Chief Scientific Officer
10 Apr 2026 7 min read
Blog Human challenge trials Infectious diseases

Tripledemic Takedown: How Human Challenge Trials are Ideal to Expedite Multivalent Vaccine Development

Andrew Catchpole
Andrew Catchpole Chief Scientific Officer
10 Apr 2026 9 min read
Blog Laboratory Human challenge trials

Empowering Next‑Gen Infectious Disease & Vaccine Development

hVIVO
hVIVO hVIVO have put this content together with subject matter experts
10 Apr 2026 3 min read
Blog Human challenge trials Trial design

Human Challenge Studies: Their Conduct and Safety Aspects

Andrew Catchpole
Andrew Catchpole Chief Scientific Officer
10 Apr 2026 9 min read
Blog Human challenge trials Infectious diseases

The UK Regulatory Competitiveness in an ever changing world

Andrew Catchpole
Andrew Catchpole Chief Scientific Officer
10 Apr 2026 4 min read
Blog Laboratory Human challenge trials

Enhancing Our Full-Service Offering: hVIVO’s New Bacteriology Lab

Chris Forsdyke
Chris Forsdyke Head of Laboratory Services
10 Apr 2026 6 min read
Case Study Blog Human challenge trials

EMA’s updated guideline to include broader coverage on Human Challenge Trials

Vi Stuart
Vi Stuart Regulatory Affairs Consultant.
10 Apr 2026 3 min read
Blog Article Laboratory

Why NGS Is the Missing Link in Early‑Phase Infectious Disease Research

Martin Larke
Martin Larke
24 Mar 2026 6 min read

    Infectious Disease Research: From Pathogen Science to Clinical Proof-of-Concept

    hVIVO is a world leader in infectious disease research, combining decades of virology expertise with validated human challenge models, BSL-2 and BSL-3 facilities, and integrated early-phase clinical and laboratory operations. Our platform supports the full development journey - from pathogen selection and model development through to high-resolution evaluation of vaccines and therapeutics against influenza, RSV, hMPV, HRV, COVID-19, and emerging priority pathogens. Whether you are advancing a first-in-human study or seeking proof-of-concept data, our end-to-end infectious disease capabilities are designed to accelerate your programme with precision and confidence. 

    FAQ

    Get in touch with us

     hVIVO’s scientific leadership is anchored in respiratory infectious diseases, supported by decades of virology expertise and a broad portfolio of validated Human Challenge Models—including influenza, RSV, hMPV, HRV, COVID19 and other priority pathogens. 

     hVIVO operates advanced Containment Level 2 and Level 3 (BSL2 / BSL3) clinical and laboratory facilities, including a stateoftheart Human Challenge Unit and onsite BSL3 laboratories.
    These facilities are complemented by a multifaceted infectious disease laboratory covering molecular, bacteriology, immunology and virology platforms.  
     hVIVO delivers comprehensive early phase development support, from pathogen/model selection and protocol design through to full regulatory alignment and execution of Human Challenge Studies.
    This integrated clinical laboratory ecosystem enables high resolution evaluation of host–pathogen dynamics and accelerates data generation for novel vaccines and therapeutics  

    Accelerate Your Infectious Disease Programme

    Contact Us